The Future of Human Diseases
About CELLULARIS
We are a deep-tech company that provides state-of-the-art 3D of human disease for the discovery of new biological targets and screening candidate therapies in the preclinical phase.
Cellularis’ leverages on deep expertise in bioengineering, cell-technologies, 3D biofabrication, and biochemistry, providing living screening platforms and expert advice for preclinical drug discovery and development pipelines.
INNOVATE
DEVELOP
PROVIDE
Next-Generation 3D In vitro Models of Human Disease with Bioengineering Tools
Our Goals
Optimizing Clinical Trials
The company’s intent is to provide greater precision, efficiency, and cost-effectiveness in the drug development pipeline via 3D disease models in vitro that deliver a better correlation with clinical trials and patient therapeutic outcomes.
Protect and Improve Animal Welfare
Cellularis’ ambition lies in providing a viable alternative to animal testing and reducing its use in clinical trials, being fully in line with current regulatory agencies’ guidelines (FDA Advancement Act 2022).
Build Partnerships
We seek to work closely with pharmaceutical companies, research centers, and healthcare providers in developing pharmaceuticals and new in vitro technologies of disease models.
Meet Our Team!
We are delighted to introduce you to the exceptional people who drive Cellularis forward.
Guided by visionary leaders and driven by the dedication of skilled professionals, our team embodies the values of collaboration, excellence and perseverance. With a wealth of expertise spanning multiple disciplines, our diverse team play a pivotal role in our mission, combining their distinct talents, viewpoints and ingenuity to fuel innovation.
Get to know the team behind Cellularis Biomodels.
